Astria Therapeutics Completes Merger and Goes Private
TipRanks (Fri, 23-Jan 5:37 PM ET)
Astria Stockholders Vote to Approve Acquisition by BioCryst
Business Wire (Wed, 21-Jan 4:00 PM ET)
PRNewswire (Thu, 8-Jan 12:50 PM ET)
PRNewswire (Wed, 7-Jan 5:12 PM ET)
Globe Newswire (Sat, 20-Dec 11:31 AM ET)
PRNewswire (Fri, 19-Dec 5:00 PM ET)
PRNewswire (Mon, 1-Dec 6:59 PM ET)
PRNewswire (Mon, 1-Dec 3:20 PM ET)
Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights
Globe Newswire (Sat, 22-Nov 5:41 AM ET)
PRNewswire (Fri, 21-Nov 5:30 PM ET)
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Astria Therapeutics trades on the NASDAQ stock market under the symbol ATXS.
As of January 27, 2026, ATXS stock price was flat at $12.58 with million shares trading.
ATXS has a beta of 1.18, meaning it tends to be more sensitive to market movements. ATXS has a correlation of 0.07 to the broad based SPY ETF.
ATXS has a market cap of $718.13 million. This is considered a Small Cap stock.
Last quarter Astria Therapeutics reported $706,000 in Revenue and -$.55 earnings per share. This fell short of revenue expectation by $-12 million and missed earnings estimates by -$.13.
In the last 3 years, ATXS traded as high as $16.90 and as low as $3.56.
The top ETF exchange traded funds that ATXS belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
ATXS has outperformed the market in the last year with a return of +69.8%, while the SPY ETF gained +15.7%. However, in the most recent history, ATXS shares have underperformed the stock market with its stock returning +1.1% in the last 3 month period and -1.1% for the last 2 week period, while SPY has returned +3.1% and +0.2%, respectively.
ATXS support price is $12.43 and resistance is $12.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATXS shares will trade within this expected range on the day.
